Pharma BD Deal Intelligence
Cephalon, Inc. / Ception Therapeutics
2010 · Acquisition/Merger · $250M · Complete
Announcement Sentiment
79
Strongly positive
Cephalon exercised option to acquire Ception for $250M following positive Phase 2 eosinophilic asthma data on reslizumab.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Pipeline outcome
Assets Advanced
Assessment window: 15yr post-close.
Key facts
- Announced Feb 22, 2010
- Closed Apr 08, 2010
- Deal value $250M
- Deal type Acquisition/Merger
- Therapeutic area Eosinophilic asthma
- Indications Eosinophilic asthma
- Key assets Reslizumab (Cinqair)
- Mechanism Anti-IL-5 monoclonal antibody
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals